IMPT-314 is under clinical development by ImmPACT Bio USA and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase I drugs for Refractory Chronic Lymphocytic Leukemia (CLL) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IMPT-314’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMPT-314 overview
IMPT-314 is under investigation for the treatment of treatment of diffuse large B cell lymphoma, refractory chronic lymphocytic leukemia (CLL), aggressive B-cell (primary mediastinal B-Cell lymphoma), follicular lymphoma and mantle cell lymphoma. It is administered intravenously. The therapeutic candidate consists of autologous T cells encoding chimeric antigen receptor (CAR) targeting CD19 and CD20. It acts by targeting CD19 and CD20 expressing cancer cells.
ImmPACT Bio USA overview
ImmPACT-Bio USA Inc (ImmPACT-Bio) is a clinical-stage company that discovers and transforms chimeric antigen receptor (CAR) T-cell therapies to address biological challenges in treating cancer and autoimmune diseases using CAR T-cell platforms. The company’s pipeline products include IMPT-314, IMPT- 514 and TBD. Its pipeline candidates treat aggressive B-cell lymphoma, lupus nephritis, and gastric cancer. The company was funded by Decheng Capital, Foresite Capital, JVC investment partners, Takeda, and others. ImmPACT Bio is headquartered in Los Angeles, California, the US.
For a complete picture of IMPT-314’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
